Population Pharmacokinetics Model of Thioguanine in Patients with Inflammatory Bowel Disease
This study presents the first PopPK model of thioguanine for IBD, offering a novel tool for MIPD in clinical settings. Future studies should explore additional covariates such as TPMT genotype and drug interactions to further refine dosing recommendations for diverse patient populations.
Authors
- Nanne K.H. de Boer (ORCID: https://orcid.org/0000-0001-8357-9887)
- Ahmed B. Bayoumy (ORCID: https://orcid.org/0000-0002-5302-9312)
- Ron J. Keizer (ORCID: https://orcid.org/0000-0002-2460-7056)
- Luc J. J. Derijks (ORCID: https://orcid.org/0000-0002-6038-9295)
Institutions
- Radboud University Nijmegen (NL)
- Maastricht University (NL)
- Máxima Medisch Centrum (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1007/s40262-025-01532-1
- Citations
- 3
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 3.14